C12-200|CAS 1220890-25-4|DC Chemicals

Cas No.:	1220890-25-4
Chemical Name:	C12-200
Synonyms:	Tech G 1
SMILES:	C(O)(CCCCCCCCCC)CN(CC(O)CCCCCCCCCC)CCN1CCN(CCN(CCN(CC(O)CCCCCCCCCC)CC(O)CCCCCCCCCC)CC(CCCCCCCCCC)O)CC1
Formula:	C₇₀N₅O₅H₁₄₅
M.Wt:	1136.931
Purity:	>95%
Sotrage:	pure form: -20°C/3 years,4°C/2 years; In solvent: -20°C/1 month
Publication:	1. Kevin T. Love, Kerry P. Mahon, Christopher G. Levins, Kathryn A. Whitehead, William Querbes, J. Robert Dorkin, June Qin, William Cantley, Liu Liang Qin, Timothy Racie, Maria Frank-Kamenetsky, Ka Ning Yip, Rene Alvarez, Dinah W. Y. Sah, Antonin de Fougerolles, Kevin Fitzgerald, Victor Koteliansky, Akin Akinc, Robert Langer, Daniel G. Anderson, Proceedings of the National Academy of Sciences, Feb 2010, 107 (5) 1864-1869; DOI: 10.1073/pnas.0910603106 2. Leuschner F, Courties G, Dutta P, Mortensen LJ, Gorbatov R, Sena B, Novobrantseva T, Borodovsky A, Fitzgerald K, Koteliansky V, Iwamoto Y, Bohlender M, Meyer S, Lasitschka F, Meder B, Katus HA, Lin C, Libby P, Swirski FK, Anderson DG, Weissleder R, Nahrendorf M. Eur Heart J. 2015 Jun 14;36(23):1478-88. doi: 10.1093/eurheartj/ehu225. Epub 2014 Jun 20. 3. Kauffman KJ, Dorkin JR, Yang JH, Heartlein MW1, DeRosa F1, Mir FF, Fenton OS, Anderson DG. Nano Lett. 2015 Nov 11;15(11):7300-6. doi: 10.1021/acs.nanolett.5b02497. Epub 2015 Oct 20.

Description:

C12-200 is a cationic lipid for Lipid NanoParticles as delivery systems for enabling the therapeutic potential of siRNA, mRNA or CRISPR as they exhibit remarkable in vivo potencies at low doses.C12-200 is a common positive control ionizable lipid for exploring new ionizable lipids. C12-200 is an ionizable lipid with five tails. The tri-palmitoyl-Sglyceryl cysteine linked to the pentapeptide (Pam3)-modified C12-200 iLNPs was developed to deliver tumor antigen mRNA for enhancing the mRNA-mediated cancer immunotherapy. The results of the therapeutic evaluation showed that Pam3- modified C12-200 iLNPs could almost inhibit tumor growth in tumor-bearing mice. To improve delivery efficiency, the formulation was optimized to replace the phospholipids from DSPC to DOPE, and the result showed that optimized formulation induced EPO protein expression was seven times that of the initial formulation,[35] and the formulation has been used in the study for mRNA-mediated human α-galactosidase protein replacement therapy in mice and nonhuman primates.

References:

1. Kevin T. Love, Kerry P. Mahon, Christopher G. Levins, Kathryn A. Whitehead, William Querbes, J. Robert Dorkin, June Qin, William Cantley, Liu Liang Qin, Timothy Racie, Maria Frank-Kamenetsky, Ka Ning Yip, Rene Alvarez, Dinah W. Y. Sah, Antonin de Fougerolles, Kevin Fitzgerald, Victor Koteliansky, Akin Akinc, Robert Langer, Daniel G. Anderson, Proceedings of the National Academy of Sciences, Feb 2010, 107 (5) 1864-1869; DOI: 10.1073/pnas.0910603106 2. Leuschner F, Courties G, Dutta P, Mortensen LJ, Gorbatov R, Sena B, Novobrantseva T, Borodovsky A, Fitzgerald K, Koteliansky V, Iwamoto Y, Bohlender M, Meyer S, Lasitschka F, Meder B, Katus HA, Lin C, Libby P, Swirski FK, Anderson DG, Weissleder R, Nahrendorf M. Eur Heart J. 2015 Jun 14;36(23):1478-88. doi: 10.1093/eurheartj/ehu225. Epub 2014 Jun 20. 3. Kauffman KJ, Dorkin JR, Yang JH, Heartlein MW1, DeRosa F1, Mir FF, Fenton OS, Anderson DG. Nano Lett. 2015 Nov 11;15(11):7300-6. doi: 10.1021/acs.nanolett.5b02497. Epub 2015 Oct 20.

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101

Cat. No.	Product name	Field of application
DC12145	DLinDMA	DLinDMA is a key lipid component of stable nucleic acid lipid particles as a benchmark.
DC40169	DMG-PEG2000	DMG-PEG 2000 is used for the preparation of liposome for siRNA delivery with improved transfection efficiency in vitro. DMG-PEG 2000 is also used for the lipid nanoparticle for an oral plasmid DNA delivery approach in vivo through a facile surface modific
DC59010	C14-4 (C14-494,Lipid B-4,Lipid B4)	C14-4 (C14-494,Lipid B-4,Lipid B4) is a novel ionizable lipid with the highest T-cell transfection efficiency and low cytotoxicity.The C14-4 ionizable lipid has been explored for CAR-T therapy.To screen the excellent formulations for mRNA delivery, a lipid library of 24 ionizable lipids was constructed to make iLNPs, which were used to deliver luciferase mRNA into Jurkat cells.[115] The optimal iLNPs formulation was C14-4 iLNPs (C14-4 ionizable lipid, DOPE, chol, and PEG at a molar ratio of 35%, 16%, 46.5%, and 2.5%) (Figure 6c). The optimal dose of luciferase mRNA for C14-4 iLNPs was 30 ng. Compared with electroporated CAR T cells, the CAR T cells engineered via C14-4 iLNPs showed potent cancer-killing activity when they were cocultured with Nalm-6 acute lymphoblastic leukemia cells. To obtain a safer and more effective CAR mRNA delivery vehicle, the orthogonal design provided 256 potential formulations, and 16 representative iLNPs formulations were evaluated.Through evaluating the safety, delivery efficiency, and transfection efficiency of 16 iLNPs, the formulation B10 (C14-4 ionizable lipid, DOPE, chol, PEG at a molar ratio of 40%, 30%, 25%, and 2.5%) was screened out as the optimal performing formulation. The luciferase expression based on B10 formulation was increased threefold than the initial formulation. Reducing the accumulation and clearance of iLNPs in the liver can increase the expression of CAR mRNA in T cells, further improving the therapeutic effect of CAR-T. Studies have shown that cholesterol analogs can alter the mechanisms of intracellular circulation and enhance the delivery of mRNA, which may be related to the reduced recognition of iLNPs by the Niemann Pick C1 (NPC1) enzyme.The addition of a hydroxyl group to various locations in the cholesterol molecule can alter the binding kinetics between the modified cholesterol and NPC1, and reduced NPC1 recognition of cholesterol. The results showed that replacement of 25% and 50% 7 α-hydroxycholesterol for cholesterol in iLNPs improved mRNA delivery to primary human T cells in vitro by 1.8-fold and twofold, respectively.C14-4 is one of the ionizable lipids to efficiently deliver mRNA to Jurkat cells or primary human T cells. It will effectively promote the development of mRNA delivery by iLNPs for CAR-T therapy.
DC52028	MVL5	MVL5 is a new Multivalent Cationic Lipid for siRNA Delivery.Improved total gene silencing and Lower non-specific gene silencing,Lower toxicity.
DC53130	93-O17S	93-O17S is an imidazole-based synthetic lipidoid for in vivo mRNA delivery. Lipid nanoparticles (LNPs) with 93-O17S promotes both the cross-presentation of tumor antigens and the intracellular delivery of cGAMP (STING agonist).
DC52020	ALC-0159	ALC-0159 is a PEG/lipid conjugate (i.e. PEGylated lipid). Formulations containing ALC-0159 have been used in the development of lipid nanoparticles (LNPs) for the delivery of mRNA-based vaccines.
DC57046	ATX-126(ATX-0126, lipid 10p)	ATX-126(ATX-0126, 10p) is an ionizable cationic lipid (pKa = 6.38).It has been used in the generation of lipid nanoparticles (LNPs) for the delivery of siRNA. Intravenous administration of LNPs containing ATX-126(ATX-0126, 10p) and encapsulating Factor VII siRNA decrease Factor VII blood levels in mice.
DC59002	ssPalmO-Phe(SS-OP)	ssPalmO-Phe(SS-OP) is a self-degradable material for the delivery of oligonucleotides. ssPalmO-Phe is a self-degradable derivative of ssPalm that is self-degraded in the intraparticle space by a specific hydrolytic reaction. ssPalmO-Phe is beneficial for overcoming the plasma/endosomal membrane, LNP-ssPalmO-Phe can be used to deliver both nucleic acids.
DC57008	BAMEA-O16B	BAMEA-O16B is a disulfide bond-containing ionizable cationic lipid. BAMEA-O16B, a lipid nanoparticle integrated with disulfide bonds, can efficiently deliver Cas9 mRNA and sgRNA into cells while releasing RNA in response to the reductive intracellular environment for genome editing as fast as 24 h post mRNA delivery.
DC58046	C12-200	C12-200 is a cationic lipid for Lipid NanoParticles as delivery systems for enabling the therapeutic potential of siRNA, mRNA or CRISPR as they exhibit remarkable in vivo potencies at low doses.C12-200 is a common positive control ionizable lipid for exploring new ionizable lipids. C12-200 is an ionizable lipid with five tails. The tri-palmitoyl-Sglyceryl cysteine linked to the pentapeptide (Pam3)-modified C12-200 iLNPs was developed to deliver tumor antigen mRNA for enhancing the mRNA-mediated cancer immunotherapy. The results of the therapeutic evaluation showed that Pam3- modified C12-200 iLNPs could almost inhibit tumor growth in tumor-bearing mice. To improve delivery efficiency, the formulation was optimized to replace the phospholipids from DSPC to DOPE, and the result showed that optimized formulation induced EPO protein expression was seven times that of the initial formulation,[35] and the formulation has been used in the study for mRNA-mediated human α-galactosidase protein replacement therapy in mice and nonhuman primates.